Literature DB >> 28575457

Characterizing Adult Cervical Deformity and Disability Based on Existing Cervical and Adult Deformity Classification Schemes at Presentation and Following Correction.

Peter G Passias1, Cyrus M Jalai1, Justin S Smith2, Virginie Lafage3, Bassel G Diebo3, Themistocles Protopsaltis1, Gregory Poorman1, Subaraman Ramchandran1, Shay Bess1, Christopher I Shaffrey2, Christopher P Ames4, Frank Schwab3.   

Abstract

BACKGROUND: Adult cervical deformity (ACD) classifications have not been implemented in a prospective ACD population and in conjunction with adult spinal deformity (ASD) classifications.
OBJECTIVE: To characterize cervical deformity type and malalignment with 2 classifications (Ames-ACD and Schwab-ASD).
METHODS: Retrospective review of a prospective multicenter ACD database. Inclusion: patients ≥18 yr with pre- and postoperative radiographs. Patients were classified with Ames-ACD and Schwab-ASD schemes. Ames-ACD descriptors (C = cervical, CT = cervicothoracic, T = thoracic, S = coronal, CVJ = craniovertebral) and alignment modifiers (cervical sagittal vertical axis [cSVA], T1 slope minus cervical lordosis [TS-CL], modified Japanese Ortphopaedic Association [mJOA] score, horizontal gaze) were assigned. Schwab-ASD curve type stratification and modifier grades were also designated. Deformity and alignment group distributions were compared with Pearson χ2/ANOVA.
RESULTS: Ames-ACD descriptors in 84 patients: C = 49 (58.3%), CT = 20 (23.8%), T = 9 (10.7%), S = 6 (7.1%). cSVA modifier grades differed in C, CT, and T deformities (P < .019). In C, TS-CL grade prevalence differed (P = .031). Among Ames-ACD modifiers, high (1+2) cSVA grades differed across deformities (C = 47.7%, CT = 89.5%, T = 77.8%, S = 50.0%, P = .013). Schwab-ASD curve type and presence (n = 74, T = 2, L = 6, D = 2) differed significantly in S deformities (P < .001). Higher Schwab-ASD pelvic incidence minus lumbar lordosis grades were less likely in Ames-ACD CT deformities (P = .027). Higher pelvic tilt grades were greater in high (1+2) cSVA (71.4% vs 36.0%, P = .015) and high (2+3) mJOA (24.0% vs 38.1%, P = .021) scores. Postoperatively, C and CT deformities had a trend toward lower cSVA grades, but only C deformities differed in TS-CL grade prevalence (0 = 31.3%, 1 = 12.2%, 2 = 56.1%, P = .007).
CONCLUSION: Cervical deformities displayed higher TS-CL grades and different cSVA grade distributions. Preoperative associations with global alignment modifiers and Ames-ACD descriptors were observed, though only cervical modifiers showed postoperative differences.
Copyright © 2017 by the Congress of Neurological Surgeons

Entities:  

Keywords:  Adult cervical deformity; Ames cervical spine deformity; Classification; Correction; Deformity descriptor; Modifier; SRS-Schwab adult spinal deformity

Mesh:

Year:  2018        PMID: 28575457     DOI: 10.1093/neuros/nyx175

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  3 in total

Review 1.  Adult cervical deformity: radiographic and osteotomy classifications.

Authors:  Bassel G Diebo; Neil V Shah; Maximillian Solow; Vincent Challier; Carl B Paulino; Peter G Passias; Renaud Lafage; Frank J Schwab; Han Jo Kim; Virginie Lafage
Journal:  Orthopade       Date:  2018-06       Impact factor: 1.087

2.  Prioritization of realignment associated with superior clinical outcomes for surgical cervical deformity patients.

Authors:  Katherine E Pierce; Peter Gust Passias; Avery E Brown; Cole A Bortz; Haddy Alas; Renaud Lafage; Oscar Krol; Dean Chou; Douglas C Burton; Breton Line; Eric Klineberg; Robert Hart; Jeffrey Gum; Alan Daniels; Kojo Hamilton; Shay Bess; Themistocles Protopsaltis; Christopher Shaffrey; Frank A Schwab; Justin S Smith; Virginie Lafage; Christopher Ames
Journal:  J Craniovertebr Junction Spine       Date:  2021-09-08

3.  Diagnostic Value of T1 Slope in Degenerative Cervical Spondylotic Myelopathy.

Authors:  Jin Sun; Hong-Wei Zhao; Jun-Jie Wang; Liang Xun; Na-Xin Fu; Hui Huang
Journal:  Med Sci Monit       Date:  2018-02-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.